

# Lyndra Therapeutics to collaborate with Gilead Sciences

Client News

July 9, 2019

Gunderson Dettmer client Lyndra Therapeutics has entered into a partnership agreement with Gilead Sciences to develop and commercialize ultra-long-acting oral HIV therapies. Gilead will have exclusive rights to Lyndra's therapeutics platform for ultra-long-acting formulations related to HIV.

In the [announcement of the collaboration](#) Lyndra Therapeutics CEO and cofounder Amy Schulman said, "Gilead has led the way in HIV prevention and treatment by focusing on reducing pill burden through the development of single-tablet oral regimens for their therapies, addressing an epidemic that affects nearly 40 million people globally. At Lyndra, our commitment to HIV is foundational and we are delighted to continue to work with strong research and development partners such as the Bill & Melinda Gates Foundation and, now, Gilead."

The Gunderson Dettmer team representing Lyndra was led by Tim Ehrlich and included Joel Diamond.

## Related People





Timothy H. Ehrlich  
PARTNER  
P +1 617 648 9399



Joel T. Diamond  
ASSOCIATE  
P +1 617 648 9136

## Featured Insights

### CLIENT NEWS

Anduril Announces Acquisition of Klas to Advance Tactical Edge Computing and Communications

### FIRM NEWS

Gunderson Dettmer Commemorates 2025 Asian American and Pacific Islander Heritage (AAPI) Month

### CLIENT NEWS

Prosus Leads US\$7.25M Financing of Zapia

### CLIENT NEWS

Brazilian Carbon Capture Company Mombak Announces \$30M Financing

### CLIENT NEWS

Latin American Fintech Clara Announces \$80 Million Financing

#### CLIENT NEWS

Africa B2B OmniRetail Announces \$20M Financing

#### CLIENT NEWS

Glacier Announces Series A Financing to Expand Robot Recycling Fleet

#### CLIENT NEWS

Dataminr Announces \$100M Investment Led by Fortress Investment Group

#### CLIENT NEWS

Omnidian Announces \$87M Series C for Renewable Energy Performance

#### INSIGHTS

Splitting the Pie: How Savvy Founders Divide Ownership and Navigate Other Founder Equity Decisions

#### CLIENT NEWS

Chainguard Announces \$356 Million Series D Led by Kleiner Perkins and IVP

#### INSIGHTS

Client Insight: California AI Transparency Act